Impact of Preventive Therapy with Nadolol and Topiramate on the Quality Of Life Of Migraine Patients

Cephalalgia ◽  
2007 ◽  
Vol 27 (8) ◽  
pp. 920-928 ◽  
Author(s):  
JC Garcia-Monco ◽  
N Foncea ◽  
A Bilbao ◽  
I Ruiz de Velasco ◽  
M Gomez-Beldarrain
Keyword(s):  
Quality Of Life ◽  
Depression Scale ◽  
Preventive Therapy ◽  
Anxiety And Depression ◽  
Physical Domain ◽  
Depressive State ◽  
Migraine Frequency ◽  
Sf 36 ◽  
The Impact

Preventive therapy is aimed at reducing migraine frequency, but should also improve the much deteriorated quality of life of the migraneur. We aimed to evaluate the impact of preventive therapy with two widely employed drugs (topiramate and nadolol) on the quality of life of migraine patients. A population of consecutive migraineurs aged ≥16 years, with frequent migraines, was selected prospectively for evaluation at baseline and after 16 weeks of therapy with nadolol or topiramate (40 mg and 100 mg daily, respectively) by generic and specific quality of life questionnaires (SF-36 and MSQOL) and by an anxiety and depression scale (HADS). Preventive therapy resulted in a statistically significant improvement in physical domains of the SF-36, whereas mental domains remained almost unchanged. Despite this improvement, all domains remained below the population norms. The HADS revealed a moderate depressive state at baseline that did not change with therapy. The MSQOL global score also revealed statistically significant improvement. Both drugs were similarly effective, although topiramate was superior on the role physical domain compared with nadolol. Preventive therapy with nadolol and topiramate significantly improves the quality of life of migraineurs, although additional efforts are needed to place them in a nearer-to-normal situation compared with the general population.

scholarly journals Quality of life is decreased in female patients treated for microprolactinoma

2007 ◽  
Vol 157 (2) ◽  
pp. 133-139 ◽  
Author(s):  
M Kars ◽  
A A van der Klaauw ◽  
C S Onstein ◽  
A M Pereira ◽  
J A Romijn
Keyword(s):  
Quality Of Life ◽  
Short Form ◽  
Nottingham Health Profile ◽  
Depression Scale ◽  
Well Being ◽  
Anxiety And Depression ◽  
Female Patients ◽  
Sf 36 ◽  
The Impact

Objective: Most studies on treatment of microprolactinoma have focused on clinical and biochemical outcome rather than on functional and mental well-being. We evaluated this topic in female patients with microprolactinoma, because other pituitary adenomas are associated with decreased quality of life. Design: We conducted a cross-sectional study. Patients and methods: To assess the impact of treatment for microprolactinoma on subjective well-being, quality of life was investigated in 55 female patients (mean age 45 ± 10 years), treated for microprolactinoma in our center, using four validated, health-related questionnaires: Short-Form-36 (SF-36), Nottingham Health Profile (NHP), Multidimensional Fatigue Inventory (MFI-20), and Hospital Anxiety and Depression Scale (HADS). Patient outcomes were compared with those of 183 female controls with equal age distributions. Results: Anxiety and depression scores were increased when compared with controls for all subscales as measured by HADS, and fatigue for all but one subscale as measured by MFI-20. Patients treated for microprolactinoma had worse scores on social functioning, role limitations due to physical problems (SF-36), energy, emotional reaction, and social isolation (NHP) when compared with control subjects. Important independent predictors of quality of life were reproductive status and anxiety and depression scores according to the HADS. Conclusion: Quality of life is impaired in female patients treated for microprolactinoma, especially due to increased anxiety and depression. These increased anxious and depressive feelings might be due to possible effects of hyperprolactinemia on the central nervous system. Failure to recognize this association may adversely affect patient–doctor relationships.

Psychophysical functioning and quality of life in 94 patients affected by oropharyngeal cancer and treated with different therapeutic approaches.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 6039-6039
Author(s):  
Fulvia Pedani ◽  
Mario Airoldi ◽  
Massimiliano Garzaro ◽  
Riccardo Torta ◽  
Luca Raimondo ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Psychological Functioning ◽  
Depression Scale ◽  
Stage Iv ◽  
Stage Iii ◽  
Lower Percentage ◽  
Anxiety And Depression ◽  
Anxiety Depression ◽  
The Impact

6039 Background: The treatment of oropharyngeal squamous cell carcinomas (OSCC) may heavily affect patient’s quality of life (QoL). Aim of our study was the evaluation of the impact of different treatments on physical and psychological functioning and on QoL of patients affected by stage III-IV disease. Methods: The enrolled sample was composed by 94 OSCC patients divided into 3 subgroups based on treatment modalities: surgery + adjuvant radiotherapy (S + RT: 30 patients), exclusive concomitant chemo-radiotherapy (CT + RT: 30 patients) and exclusive chemotherapy (CT) in 34 patients not suitable for surgery and/or radiotherapy. Psycho-oncological assessment included: Hospital Anxiety Depression Scale (HADS), Montgomery-Asberg Depression Scale (MADRS), Mini-Mental Adjustment to Cancer scale (MINI-MAC), EORTC QLQ C-30 questionnaire with the specific module Head and Neck 35 (H&N35). Results: The 60 patients primarily treated with S + RT or CT + RT presented superimposeable clinical and tumour characteristics while those treated with exclusive CT were affected by stage IV disease and in the 90% of cases underwent to previous treatment exclusive or combined treatment such as surgery, radiotherapy and chemotherapy. In the following table, data about physical and psychological functioning and on QoL of the 3 subgroups of patients are summarized. Conclusions: In stage III-IV OSCC treatments have a strong influence on QoL and coping styles. Patients treated with CT + RT were characterized by a lower percentage of self-reported anxiety and depression and higher EORTC Global QoL score. More than one third of patients treated with S + RT had overt symptoms of anxiety and depression. Stage IV patients treated with palliative CT had elevated level of anxiety, depression and low quality of life. Auto-evaluation is less effective in depression assessment. The role of concomitant psychological supportive care should be evaluated in these patients treated with different approaches. [Table: see text]

scholarly journals Evaluation of the impact of high-tone therapy on cognitive disorders and quality of life in the complex treatment of patients with comorbid pathology

2021 ◽  
pp. 345-351
Author(s):  
Iryna SHMAKOVA ◽  
Svitlana PANINA ◽  
Volodymyr MYKHAYLENKO
Keyword(s):  
Quality Of Life ◽  
Cognitive Functions ◽  
Anxiety And Depression ◽  
High Tone ◽  
Complex Treatment ◽  
Group I ◽  
Sf 36 ◽  
Group Ii ◽  
The Impact

Introduction. Comorbidity is an independent risk factor for mortality and significantly influences the prognosis and quality of life. Purpose: to evaluate the impact of high-tone HiTOP 4 touch therapy on cognitive disorders and quality of life in the complex treatment of patients with comorbid pathology. Methods: complex treatment of 2 groups of patients with inclusion in the basic treatment regimen of high-tone therapy was carried out - a total of 80 patients (men - 34, women - 46) aged 41 to 79 years old, group I - patients with hypertension and chronic cerebral ischemia (CСI) - 38 patients and group II - patients with hypertension, CСI and concomitant diabetes mellitus (DM) type 2 - 42 patients. The average age in group I was 61.5, in group II - 65.5. Group I received lisinopril and amlodipine in one tablet, group II received metformin in addition to the above therapy. Both groups received a course of 10 sessions of high-tone therapy using the device HiTOP 4 touch (Germany) according to the general method: 2 electrodes on the feet, 2 on the forearms and one on the neck-collar area. All the patients were assessed for their cognitive condition, degree of anxiety and depression, and estimated for quality of life before and after a course of high-tone therapy. In order to do this, we used valid assessment tests, such as the Montreal Cognitive Assessment Scale (MoCA), the Hospital Anxiety and Depression Scale (HADS), and the SF-36 Quality of Life Questionnaire. Results: the course of high-tone therapy for patients with hypertension and CCI led to improved quality of life, on all indicators of the SF-36 scale, except for pain intensity, increased cognitive functions by 3.52 points on the MoCA scale, reduced anxiety by 2.06 points and depression by 1.92 points on the HADS scale. The course of high-tone therapy for patients with CCI, hypertension and type 2 DM resulted in a significant improvement of 5 out of 8 quality of life indicators on the SF-36 scale, cognitive functions by 2.27 points on the MoCA scale and reduced anxiety by 4.3 points, and depression by 0.53 points on the HADS scale. Conclusion: the inclusion of high-tone therapy in the complex treatment of patients with comorbid pathology improves cognitive functions, reduces anxiety and depression, improves quality of life. Keywords: comorbid pathology, high-tone therapy, cognitive functions, anxiety, depression, quality of life,

scholarly journals Assessment of the Impact of a Daily Rehabilitation Program on Anxiety and Depression Symptoms and the Quality of Life of People with Mental Disorders during the COVID-19 Pandemic

2021 ◽  
Vol 18 (4) ◽  
pp. 1434
Author(s):  
Joanna Smolarczyk-Kosowska ◽  
Anna Szczegielniak ◽  
Mateusz Legutko ◽  
Adam Zaczek ◽  
Łukasz Kunert ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Mental Health ◽  
Rehabilitation Program ◽  
Anxiety And Depression ◽  
Depression Symptoms ◽  
Sf 36 ◽  
Mental Health Support ◽  
Health Support ◽  
The Impact

Community psychiatry is a modern and effective form of care for patients with mental disorders. The aim of the study was to assess the impact of a rehabilitation program at the Mental Health Support Centre in Tarnowskie Góry (Poland) on reducing severity of anxiety and depression symptoms, as well as improving overall quality of life during the COVID-19 pandemic. The study involved 35 patients, examined with an authors’ questionnaire on sociodemographic data, the Hospital Scale of Anxiety and Depression (HADS) and the Short Form Health Survey (SF-36). Data was obtained during the first national lockdown and compared to data gathered before the pandemic on the same study group. Imposed restrictions, negative emotional state during lockdown, subjectively assessed higher health risk and a low level of knowledge about the COVID-19 pandemic did not significantly correlate with a severity of depression and anxiety, as well as general quality of life. However, the comparison of the results obtained in HADS and SF-36 scales show a significant improvement in both categories. Rehabilitation activities, including physical training, cognitive exercise and social therapy, reduce the severity of the symptoms and have a positive effect on the overall quality of life in patients suffering from schizophrenia and affective disorders. Therefore, holistic mental health support services may positively affect building an individual resilience. The severity of anxiety symptoms during the COVID-19 pandemic shows a negative correlation with the patient’s age.

scholarly journals Anxiety and depression intensity and the quality of life of patients with an implanted pacemaker

2021 ◽  
Vol 11 (6) ◽  
pp. 170-177
Author(s):  
Kamil Sikora ◽  
Robert Jan Łuczyk ◽  
Agnieszka Wawryniuk ◽  
Marta Łuczyk ◽  
Agnieszka Zwolak
Keyword(s):  
Quality Of Life ◽  
Standard Deviation ◽  
Pacemaker Implantation ◽  
Depression Scale ◽  
Anxiety Scale ◽  
Anxiety And Depression ◽  
Average Score ◽  
The Impact ◽  
Implanted Pacemaker

Introduction. The consequences of anxiety and depression in various forms affect the course of cardiovascular diseases - including patients with an implanted pacemaker. To improve the quality of care for such patients, it is important to understand the scale of the problem, as well as to determine the impact of the above-mentioned symptoms on the patients' quality of life.Aim of research. The aim of the study was to assess the relationship between the quality of life and the anxiety and depression intensity on patients with implanted pacemakers.Material and methods. The study involved 100 patients hospitalized at the SPSK 4 cardiology clinic in Lublin with an implanted pacemaker. The method of diagnostic survey and research tools were used - the WHOQOL - Bref questionnaire to assess the quality of life and the Hospital Anxiety and Depression Scale (HADS-M). The results of the research are summarized in the statistical analysis.Results. The average score obtained by the respondents on the depression scale was 6.05 points with a standard deviation of 4.47. On the anxiety scale, this result was 7.99 points with a standard deviation of 4.54. The results indicating disorders in both scales concern values higher than or equal to 11 points. On the depression scale they were obtained by 16% of the respondents, while on the anxiety scale 26%. The conducted analyses showed a statistically significant relationship between the level of anxiety and depression and the quality of life of the respondents in all domains. The overall declared quality of life of the respondents and the self-esteem of the health condition were the lower, the higher the anxiety and depression severity coefficient in the study group.Conclusions.1. Most of the studied patients with pacemakers do not have high levels of anxiety and depression. 2. The occurrence of anxiety and depression affects the quality of life of respondents after pacemaker implantation in all domains. 3. Patients with high levels of anxiety and depression have a lower assessment of their quality of life and health.

A nxiety and depression influence the relation between disability status and quality of life in multiple sclerosis

2003 ◽  
Vol 9 (4) ◽  
pp. 397-403 ◽  
Author(s):  
A CJW Janssens ◽  
P A van Doorn ◽  
J B de Boer ◽  
N F Kalkers ◽  
F GA van der Meché ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Mental Health ◽  
Multiple Sclerosis ◽  
Physical Functioning ◽  
Bodily Pain ◽  
Depression Scale ◽  
Anxiety And Depression ◽  
Sf 36 ◽  
Disability Status

Disability status, depression and anxiety are important determinants of quality of life (Q oL) in patients with multiple sclerosis (MS). We investigated whether anxiety and depression influence the relation between disability status and Q oL in our cohort of recently diagnosed patients. Disability status [Expanded Disability Status Scale (EDSS)], anxiety and depression [Hospital A nxiety and Depression Scale (HADS)], and Q oL (SF-36) were prospectively obtained in 101 MS patients. The relation between EDSS and SF-36 scales was examined using regression analyses, without and with adjustment for anxiety and depression. Interaction effects were investigated by comparing the relation between EDSS and Q oL in patients with high and low anxiety and depression. In the unadjusted analyses, EDSS was significantly related to all SF-36 physical and mental health scales. A fter adjustment for anxiety and depression, EDSS was significantly related only to the SF-36 physical functioning, role-physical functioning and bodily pain scales. The relation between EDSS and these SF-36 scales was consistently higher in patients with more symptoms of anxiety or depression, suggesting that anxiety and depression strengthened the association of EDSS in these SF-36 physical health scales. A fter adjustment for anxiety and depression, EDSS was not significantly related to the SF-36 mental health scales and the general health scale. This finding is compatible with the hypothesis that anxiety and depression are intermediate factors in the association of EDSS with these SF-36 scales. Screening for symptoms of anxiety and depression is recommended in studies that use Q oL as an outcome measure of treatment or intervention efficacy.

scholarly journals Anxiety, Depression and Quality of Life Improve After One Month and Three Months of Home Parenteral Nutrition: A Pilot Study in a Canadian Population

2018 ◽  
Vol 2 (4) ◽  
pp. 178-185
Author(s):  
Maria Ines Pinto-Sanchez ◽  
Shannon Gadowsky ◽  
Suzan McKenzie ◽  
Michael J Raphael ◽  
Anne Childs ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Parenteral Nutrition ◽  
Depression Scale ◽  
Home Parenteral Nutrition ◽  
Anxiety And Depression ◽  
Underlying Malignancy ◽  
Sf 36 ◽  
Hospital To Home ◽  
Anxiety Depression

Abstract Background Patients receiving home parenteral nutrition (HPN) have a reduced quality of life (QoL), but it is unknown if this is associated with psychiatric comorbidities such as anxiety or depression. Aim The aim of this study was to assess anxiety, depression and QoL in patients transitioning from hospital to HPN. Methods We conducted a prospective study in adult patients receiving parenteral nutrition (PN) during transition from hospital to home. We assessed anxiety and depression (Hospital Anxiety and Depression Scale; HADS), health-related quality of life (HRQoL; SF-36) and health status (EQ-5D) before discharge and again later at one and three months after HPN was started. Results Of the 29 patients, 15 had an underlying malignancy. At baseline, 93% of patients with malignancy had anxiety or depression (HADS A and/or HADS D >7) or both, while of the patients without malignancy, 60% had anxiety, and 40% had depression. Questionnaires were completed by 21 patients at one month and by 15 at three months. Anxiety and depression scores decreased significantly after one month of HPN (mean difference [MD] anxiety: 4.3; 95% CI, 1.2–7.5, P = 0.004; MD depression: 4.0; 95% CI, 1.5–6.5, P = 0.001), and the decrease persisted at three months (MD anxiety: 35; 95% CI, 0.35–6.6, P = 0.02; MD depression: 2.5; 95% CI, 0.06–5.0, P = 0.04). Overall, patients reported an improvement in HRQoL (SF-36) after one month of HPN, and this improvement was maintained at three months in those patients who survived. Conclusion Home parenteral nutrition is associated with improvements in anxiety, depression and HRQoL at one month and three months after discharge from hospital. The improvements in Qol, anxiety and depression seem greater in patients with underlying malignancy.

scholarly journals COMPARISON OF THE PREVALENCE AND DYNAMICS OF ANXIETY, DEPRESSION AND QUALITY OF LIFE IN PATIENTS WITH CHRONIC RHEUMATIC HEART DISEASE

2019 ◽  
Vol 9 (3) ◽  
pp. 222-228
Author(s):  
V. S. Petrov
Keyword(s):  
Quality Of Life ◽  
Heart Disease ◽  
Rheumatic Heart Disease ◽  
State Anxiety ◽  
Short Form ◽  
Depression Scale ◽  
Anxiety And Depression ◽  
Sf 36 ◽  
Rheumatic Heart

The objective. The assessment of the severity, prevalence and five-year dynamics of anxiety and depression in those studied with rheumatic heart disease.Materials and methods. The study included 168 patients with rheumatic heart disease: mean age 58,69±0,47 years; 141 women (83,93%) and 27 men (16,07%). To assess anxiety and depression, the following scales were used: HADS (hospital anxiety and depression scale), CES-D (depression scale of the epidemiological research center), and STAI (Spielberger anxiety scale). Quality of life was assessed using total scale SF-36 (Short Form Medical Outcomes Study), KCCQ (Kansas questionnaire for patients with cardiomyopathy), and MHFLQ (Minnesota questionnaire for the quality of life of patients with CHF).Results. Initially, patients with rheumatic heart disease had mild depression and anxiety, except for the high level of state anxiety according to STAI — 48.00 ± 0.95. More pronounced depressive disorders were revealed in patients with CHF NYHA III and IV. According to CES-D — 17,58±1,27 for FC I and 23,4±0,75 for FC IV, for HADS — 7,00±0,64 for FC I and 13,6±0,78 for FC IV. Anxiety disorders, on the contrary, were less with III and IV FC CHF: 8,5±0,49 with FC I and 8,2±1,02 with FC IV in HADS. According to STAI state anxiety — 47,58±1,22 (FC I) and 42,8±1,76 (FC IV), for trait anxiety — 42,67±1,08 (FC I) and 40,4±1,85 (FC IV). For the five-year period there was no negative and positive dynamics according to the questionnaires of anxiety and depression. The only exception was the increase in anxiety according to HADS by 0.66 points. In terms of quality of life, there was a decrease in physical health according to SF-36 by 1.78, and in overall summary score according to KCCQ by 1.55 and MHFLQ by — 3.99.Conclusions. In patients with rheumatic heart disease, the severity of anxiety and depression is insignificant and does not increase during five years of observation. Indicators of depression are more pronounced in the group with CHF NYHA III and IV, and anxiety indicators in patients with CHF NYHA I and II. An increase in depression rates in subjects with rheumatic heart disease is associated with a deterioration in the quality of life. With an improvement in the quality of life values, depressive symptoms decrease, and anxiety rates increase.

Self-Reported Distress in Patients With Ovarian Cancer: Is It Related to Disease Status?

2015 ◽  
Vol 25 (2) ◽  
pp. 229-235 ◽  
Author(s):  
Floortje K. Ploos van Amstel ◽  
Maaike A.P.C. van Ham ◽  
Esmee J. Peters ◽  
Judith B. Prins ◽  
Petronella B. Ottevanger
Keyword(s):  
Quality Of Life ◽  
Ovarian Cancer ◽  
Depression Scale ◽  
Disease Status ◽  
Anxiety And Depression ◽  
Hospital Anxiety ◽  
Impact Of Event Scale ◽  
Event Scale ◽  
The Impact

ObjectivePatients with epithelial ovarian cancer have a poor prognosis and often undergo intensive treatment. These patients are therefore at risk for experiencing distress and reduced quality of life. The aim of this study was to explore the self-reported distress severity, experienced problems, and quality of life in relation to their disease status.MethodsThis cross-sectional study was conducted in 2011 at a University Medical Center. Women with ovarian cancer (n = 273), both during and after treatment, were asked by mail to fill in self-report questionnaires. Distress was measured using with the Distress Thermometer (DT), Hospital Anxiety and Depression Scale, and Impact of Event Scale. Problems and quality of life were assessed with the problem list of the DT, and European Organization for Research and Treatment of Cancer Quality of Life C-30 and OV28.ResultsThe questionnaire data of 104 patients were analyzed. Screening with the DT revealed distress in 32% [mean (SD), 3.1 (2.6)]. Distress was found with the Hospital Anxiety and Depression Scale in 14% [8.6 (5.9)] and with the Impact of Event Scale in 18% of the patients [17.5 (15.5)]. No significant differences were found in distress severity and self-reported problems between patients with and without recurrence. In both groups, the problems fatigue, condition, and neuropathy were most reported. Patients with distress (DT ≥ 5) experienced significantly worse functioning, more problems, and lower quality of life than patients without distress (P< 0.01).ConclusionsThis study showed that disease status in patients with ovarian cancer seems to have no influence on distress, quality of life, and the problems encountered. However, distressed patients experienced more problems, with physical and emotional functioning, and had lower quality of life. The problems fatigue, physical condition, and neuropathy are the most prevailing.

Patients with Extreme Obesity: Change in Mental Symptoms Three Years after Gastric Banding

2005 ◽  
Vol 35 (2) ◽  
pp. 109-122 ◽  
Author(s):  
C. Nickel ◽  
C. Widermann ◽  
D. Harms ◽  
P. L. Leiberich ◽  
K. Tritt ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Gastric Banding ◽  
Depression Scale ◽  
Anxiety And Depression ◽  
Health Related Quality ◽  
Extreme Obesity ◽  
Sf 36 ◽  
Related Quality ◽  
Health Related

Objective: Extreme obesity causes grave psychosocial and psychopathological problems in addition to somatic morbidity. One possible treatment is gastric banding, a surgical reduction of stomach volume. The aim of this study was to investigate whether gastric banding leads to lasting change in: 1) the Body Mass Index (BMI); 2) social factors such as work and partnerships, eating behavior, anxiety and depression symptoms; and 3) health related quality of life. Method: We surveyed a sample of 50 adipose women (BMI > 40 kg/m2). Primary outcome measures were self-reported changes on the scales of the Three-Factor Eating Questionnaire (TFEQ), the Hospital Anxiety and Depression Scale (HADS-D), and the Health Survey (SF-36). Results: In comparison with the control group, we observed significant changes in BMI ( p < 0.01) and the existence of a partnership ( p < 0.01), on all three scales of the TFEQ ( p < 0.01), on both scales of the HADS-D (anxiety: p < 0.05; depression: p < 0.01), and on all scales of the SF-36 Health Survey ( p between < 0.05 and < 0.01 in every case). The most marked changes in all the qualities investigated occurred within the first 12 months of surgery. Conclusions: Three years after gastric banding, positive changes in BMI reduction, partnership, eating behavior, anxiety, depressive symptomatology, and health related quality of life could be observed. There was also a significant correlation between BMI reduction and reduction firstly on the depression scale (HADS-D) and secondly on the SF-36 scales for physical functioning (PHFU), role physical (ROPH), mental health (PSYC), and vitality (VITA).

Sign in / Sign up

Export Citation Format

Share Document